Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 6 of 6 citing Raghavan: Severe hypersensitivity pneumonitis associated with anagrelide. (0.08 sec) 

Anagrelide: a decade of clinical experience with its use for the treatment of primary …


PE Petrides - eop, 2004 - Informa Pharma Science
Primary thrombocythaemia (PT) is the most frequent among the rare chronic
myeloproliferative disorders. Life expectancy is determined by thromboembolic
and haemorrhagic complications, which can be prevented by cytoreductive ...
Cited by 13 - Related articles - All 4 versions

Double hit'from streptococcal pneumonia and hypersensitivity pneumonitis associated with …


EM Spencer, DS Lawrence - Clinical and laboratory haematology, 2006 - interscience.wiley.com
It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ...
Cited by 2 - Related articles - BL Direct - All 5 versions

Anagrelide: 20 years later


A Emadi, JL Spivak - Expert Review of Anticancer Therapy, 2009 - ingentaconnect.com
Platelets constitute the first line of defense against hemorrhage when the
integrity of the vessel wall has been compromised. As a corol- lary, a decrease
in platelet number or impair- ment of platelet function, if severe, creates ...
Cited by 1 - Related articles - All 4 versions

[PDF] DRUG NAME: Anagrelide


MOF ACTION - bccancer.bc.ca
The exact mechanism of action is not known. It is thought that a reduction in
platelet production is the result of decreased megakaryocyte hypermaturation.1
Anagrelide disrupts the postmitotic phase of megakaryocyte development, ...
Related articles - View as HTML - All 2 versions

Infiltrative lung diseases: Complications of novel antineoplastic agents in patients with …


B Vahid, PE Marik - Canadian Respiratory Journal: Journal of the Canadian …, 2008 - pubmedcentral.nih.gov
Pulmonary involvement is a common and challenging condition in patients with
hematological malignancies. Infiltrative lung diseases as a result of
antineoplastic agent-associated pulmonary toxicity are being increasingly ...
Related articles - All 2 versions

Pulmonary Complications of Novel Antineoplastic Agents for Hematologic Malignancies

- critcaremed.org
B Vahid, PE Marik - Clinical Pulmonary Medicine, 2008 - journals.lww.com
Pulmonary complications in patients with hematologic malignancies is commonly
encountered by clinicians. Some of these complications are believed to be
related to direct toxicity of the drug itself. Novel antineoplastic agents ...
Related articles - BL Direct - All 2 versions


 


Go to Google Home - About Google - About Google Scholar

©2009 Google